{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:10:21Z","timestamp":1785168621583,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"NIH","award":["DK062708"],"award-info":[{"award-number":["DK062708"]}]},{"name":"NIH","award":["KL2 TR002241"],"award-info":[{"award-number":["KL2 TR002241"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s10620-019-05858-2","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T01:02:00Z","timestamp":1569891720000},"page":"1539-1548","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Limited Progress in Hepatorenal Syndrome (HRS) Reversal and Survival 2002\u20132018: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1505-9091","authenticated-orcid":false,"given":"Mary J.","family":"Thomson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratima","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna S.","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot B.","family":"Tapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,30]]},"reference":[{"key":"5858_CR1","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/hep.20687","volume":"41","author":"C Alessandria","year":"2005","unstructured":"Alessandria C, Ozdogan O, Guevara M, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology. 2005;41:1282\u20131289.","journal-title":"Hepatology"},{"key":"5858_CR2","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/j.1572-0241.2005.40952.x","volume":"100","author":"A Cardenas","year":"2005","unstructured":"Cardenas A. Hepatorenal syndrome: a dreaded complication of end-stage liver disease. Am J Gastroenterol. 2005;100:460\u2013467.","journal-title":"Am J Gastroenterol"},{"key":"5858_CR3","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/00000441-186304000-00002","volume":"43","author":"A Flint","year":"1863","unstructured":"Flint A. Clinical report on hydro-pneumoperitoneum based on an analysis of forty-six cases. Am J Med Sci. 1863;43:306\u2013339.","journal-title":"Am J Med Sci"},{"key":"5858_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0002-9343(70)80073-0","volume":"49","author":"M Epstein","year":"1970","unstructured":"Epstein M, Berk DP, Hollenberg NK, et al. Renal failure in the patient with cirrhosis: the role of active vasoconstriction. Am J Med. 1970;49:175\u2013185.","journal-title":"Am J Med"},{"key":"5858_CR5","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/0016-5085(79)90176-8","volume":"77","author":"Y Patrick","year":"1979","unstructured":"Patrick Y, Wong GCM, Spielberg A, Milora RV, Balint JA. The hepatorenal syndrome. Gastroenterology. 1979;77:1326\u20131334.","journal-title":"Gastroenterology"},{"key":"5858_CR6","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/gutjnl-2014-308874","volume":"64","author":"P Angeli","year":"2015","unstructured":"Angeli P, Gin\u00e8s P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015;64:531\u2013537.","journal-title":"Gut"},{"key":"5858_CR7","first-page":"1310","volume":"56","author":"F Salerno","year":"2007","unstructured":"Salerno F, Gerbes A, Gin\u00e8s P, Wong F, Arroyo V. Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis. A consensus workshop of the international ascites club. Gut. 2007;56:1310\u20131318.","journal-title":"Gut"},{"key":"5858_CR8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.amjmed.2015.12.006","volume":"129","author":"EB Tapper","year":"2016","unstructured":"Tapper EB, Bonder A, Cardenas A. Preventing and treating acute kidney injury among hospitalized patients with cirrhosis and ascites: a narrative review. Am J Med. 2016;129:461\u2013467.","journal-title":"Am J Med"},{"key":"5858_CR9","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jhep.2007.04.010","volume":"47","author":"C Alessandria","year":"2007","unstructured":"Alessandria C, Ottobrelli A, Debernardi-Venon W, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol. 2007;47:499\u2013505.","journal-title":"J Hepatol"},{"key":"5858_CR10","doi-asserted-by":"publisher","first-page":"e1579.e2","DOI":"10.1053\/j.gastro.2016.02.026","volume":"150","author":"TD Boyer","year":"2016","unstructured":"Boyer TD, Sanyal AJ, Wong F, et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology. 2016;150:e1579.e2\u2013e1589.e2.","journal-title":"Gastroenterology"},{"key":"5858_CR11","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/hep.28396","volume":"63","author":"M Cavallin","year":"2016","unstructured":"Cavallin M, Piano S, Romano A, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study. Hepatology. 2016;63:983\u2013992.","journal-title":"Hepatology"},{"key":"5858_CR12","first-page":"30","volume":"64","author":"O Goyal","year":"2016","unstructured":"Goyal O, Sidhu SS, Sehgal N, Puri S. Noradrenaline is as effective as terlipressin in hepatorenal syndrome type 1: a prospective, randomized trial. J Assoc Physicians India. 2016;64:30\u201335.","journal-title":"J Assoc Physicians India"},{"key":"5858_CR13","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1007\/s10620-007-9919-9","volume":"53","author":"S Neri","year":"2008","unstructured":"Neri S, Pulvirenti D, Malaguarnera M, et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci. 2008;53:830\u2013835. \nhttps:\/\/doi.org\/10.1007\/s10620-007-9919-9\n\n.","journal-title":"Dig Dis Sci"},{"key":"5858_CR14","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","volume":"134","author":"AJ Sanyal","year":"2008","unstructured":"Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134:1360\u20131368.","journal-title":"Gastroenterology"},{"key":"5858_CR15","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1111\/j.1572-0241.2008.01828.x","volume":"103","author":"P Sharma","year":"2008","unstructured":"Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol. 2008;103:1689.","journal-title":"Am J Gastroenterol"},{"key":"5858_CR16","first-page":"1946","volume":"12","author":"FN Silawat","year":"2011","unstructured":"Silawat FN, Shaikh MK, Lohana RK, Devrajani B, Shah S, Ansari A. Efficacy of terlipressin and albumin in the treatment of hepatorenal syndrome. World Appl Sci J. 2011;12:1946\u20131950.","journal-title":"World Appl Sci J"},{"key":"5858_CR17","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jhep.2012.01.012","volume":"56","author":"V Singh","year":"2012","unstructured":"Singh V, Ghosh S, Singh B, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol. 2012;56:1293\u20131298.","journal-title":"J Hepatol"},{"key":"5858_CR18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1046\/j.1440-1746.2003.02934.x","volume":"18","author":"P Solanki","year":"2003","unstructured":"Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol. 2003;18:152\u2013156.","journal-title":"J Gastroenterol Hepatol"},{"key":"5858_CR19","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jceh.2015.08.003","volume":"5","author":"S Srivastava","year":"2015","unstructured":"Srivastava S, Vishnubhatla S, Prakash S, Sharma H, Thakur B, Acharya SK. Randomized controlled trial comparing the efficacy of terlipressin and albumin with a combination of concurrent dopamine, furosemide, and albumin in hepatorenal syndrome. J Clin Exp Hepatol. 2015;5:276\u2013285.","journal-title":"J Clin Exp Hepatol"},{"key":"5858_CR20","first-page":"764","volume":"3","author":"H Tavakkoli","year":"2012","unstructured":"Tavakkoli H, Yazdanpanah K, Mansourian M. Noradrenalin versus the combination of midodrine and octreotide in patients with hepatorenal syndrome: randomized clinical trial. Int J Prev Med. 2012;3:764.","journal-title":"Int J Prev Med"},{"key":"5858_CR21","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s12664-018-0876-3","volume":"37","author":"RU Saif","year":"2018","unstructured":"Saif RU, Dar HA, Sofi SM, Andrabi MS, Javid G, Zargar SA. Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: a randomized controlled study. Indian J Gastroenterol. 2018;37:424\u2013429.","journal-title":"Indian J Gastroenterol"},{"key":"5858_CR22","doi-asserted-by":"publisher","first-page":"300","DOI":"10.5604\/01.3001.0010.8661","volume":"17","author":"JG Stine","year":"2018","unstructured":"Stine JG, Wang J, Cornella SL, et al. Treatment of type-1 hepatorenal syndrome with pentoxifylline: a randomized placebo controlled clinical trial. Ann Hepatol. 2018;17:300\u2013306.","journal-title":"Ann Hepatol"},{"key":"5858_CR23","first-page":"CD011532","volume":"9","author":"M Israelsen","year":"2017","unstructured":"Israelsen M, Krag A, Allegretti AS, et al. Terlipressin versus other vasoactive drugs for hepatorenal syndrome. Cochrane Database Syst Rev. 2017;9:CD011532.","journal-title":"Cochrane Database Syst Rev"},{"key":"5858_CR24","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S2468-1253(16)30157-1","volume":"2","author":"A Facciorusso","year":"2017","unstructured":"Facciorusso A, Chandar AK, Murad MH, et al. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:94\u2013102.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"5858_CR25","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/MCG.0000000000000913","volume":"52","author":"A Nanda","year":"2018","unstructured":"Nanda A, Reddy R, Safraz H, Salameh H, Singal AK. Pharmacological therapies for hepatorenal syndrome: a systematic review and meta-analysis. J Clin Gastroenterol. 2018;52:360\u2013367.","journal-title":"J Clin Gastroenterol"},{"key":"5858_CR26","first-page":"282","volume":"373","author":"MR Thursz","year":"2015","unstructured":"Thursz MR, Forrest EH, Ryder S. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015;373:282\u2013283.","journal-title":"N Engl J Med"},{"key":"5858_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.","journal-title":"Syst Rev"},{"key":"5858_CR28","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/hep.510230122","volume":"23","author":"V Arroyo","year":"1996","unstructured":"Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23:164\u2013176.","journal-title":"Hepatology"},{"key":"5858_CR29","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"5858_CR30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.dld.2018.01.123","volume":"50","author":"T Song","year":"2018","unstructured":"Song T, Rossle M, He F. Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: a systematic review and meta-analysis. Dig Liver Dis. 2018;50:323\u2013330.","journal-title":"Dig Liver Dis"},{"key":"5858_CR31","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.jhep.2015.07.004","volume":"63","author":"M Bernardi","year":"2015","unstructured":"Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015;63:1272\u20131284.","journal-title":"J Hepatol"},{"key":"5858_CR32","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.cgh.2012.02.025","volume":"10","author":"GN Kalambokis","year":"2012","unstructured":"Kalambokis GN, Mouzaki A, Rodi M, et al. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. Clin Gastroenterol Hepatol. 2012;10:815\u2013818.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5858_CR33","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1007\/s10620-016-4313-0","volume":"61","author":"T Dong","year":"2016","unstructured":"Dong T, Aronsohn A, Gautham Reddy K, Te HS. Rifaximin decreases the incidence and severity of acute kidney injury and hepatorenal syndrome in cirrhosis. Dig Dis Sci. 2016;61:3621\u20133626. \nhttps:\/\/doi.org\/10.1007\/s10620-016-4313-0\n\n.","journal-title":"Dig Dis Sci"},{"key":"5858_CR34","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/hep.27709","volume":"62","author":"M Cavallin","year":"2015","unstructured":"Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology. 2015;62:567\u2013574.","journal-title":"Hepatology"},{"key":"5858_CR35","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","volume":"134","author":"M Martin-Llahi","year":"2008","unstructured":"Martin-Llahi M, Pepin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008;134:1352\u20131359.","journal-title":"Gastroenterology"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-019-05858-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-019-05858-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-019-05858-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T23:41:35Z","timestamp":1601336495000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-019-05858-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,30]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["5858"],"URL":"https:\/\/doi.org\/10.1007\/s10620-019-05858-2","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,30]]},"assertion":[{"value":"29 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors have no conflict of interests that pertain to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}